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twice daily radiation, those in the GD arm once daily, 
according to published protocols. All patients initially had 
a maximal transurethral resection and induction CRT to 
40Gy followed by cystoscopic assessment of response. 
Patients with a complete response (CR) received 
consolidation CRT to 64 Gy. Others were offered 
immediate cystectomy and no further CRT. Adjuvant 
gemcitabine/cisplatin chemotherapy was subsequently 
administered. The primary endpoint was the rate of 
distant metastasis at 3 years (DM3). Toxicity and other 
efficacy related endpoints including CR and bladder 
intact distant metastasis free survival at 3 years 
(BIDMFS3) were also assessed. Using the Clopper-Pearson 
exact binomial method, the study required 32 analyzable 
patients for each arm, with a benchmark DM3 rate of 25% 
and a 1-sided significance level of 0.1. A treatment is 
considered of potential benefit, if the observed DM3 rate 
is <25%. If both arms meet this toxicity either could be 
used to select a regimen for a future trial. The study was 
not designed to statistically compare the treatment arms 
to each other. 
Results  
From 12/2008 to 4/2014, 70 patients were enrolled and 
66 were eligible for analysis, 33 in each arm. Median 
follow-up is 4.3 years (range 0.4-7.8). DM3 was 22% and 
16% for FCT and GD, respectively. BIDMFS3 was 67% and 
72%, respectively. Post induction CR rates were 88% and 
78%, respectively. Of 33 patients in the FCT group, 32 
(97%) completed induction, 27 (93%) completed induction 
and consolidation, and 18 (54%) completed the entire 
protocol with adjuvant chemotherapy. Of 33 patients in 
the GD group, these figures were 31 (94%), 23 (92%), and 
16 (48%), respectively. Of 33 patients in the FCT group, 
21 (64%) had grade 3-4 toxicities during protocol 
treatment with 18 (54%), 2 (6%) and 2 (6%) experiencing 
grade 3-4 hematologic, gastrointestinal and genitourinary 
toxicity, respectively. For 33 patients in the GD group, 
these figures were 18 (54%) overall and 14 (42%), 3 (9%) 
and 2 (6%), respectively. 
Conclusion  
Both regimens offer similar, low 3-year metastatic rates 
of <25% although there was less toxicity in the GD arm. 
The latter also offered the convenience of once, rather 
than twice, per day radiation. 
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Purpose or Objective  
Movement and deformation make the radiotherapy 
treatment of muscle invasive bladder cancer (MIBC) 
challenging. Adaptive techniques based on ‘plan of the 
day’ have been developed with the aim of improving 
accuracy and reducing toxicity. We report the first 
randomised phase II trial of this approach in the context 
of hypofractionated radiotherapy treatment to the 
bladder in patients (pts) not fit for radical daily 
radiotherapy. 
Material and Methods  
Methods Pts with T2-T4aN0M0 MIBC had 36 Gy in 6 
fractions over 6 weeks & were randomised (1:1) to 
standard (SP) or adaptive planning (AP). The SP group had 
RT with 1 plan and the AP with plans (small, medium, 
large); margins applied are given in Table 1 and for AP 
best fitting ‘plans of the day’ selected with pre-RT cone 
beam (CB) CT . A QA programme aided standardised CBCT 
image interpretation. 
 
 
Purpose : exclude ≥30% grade(Gd) ≥3 (≥G3) acute (to 3 
months (m)) non-genitourinary (GU) toxicity for AP 
(p0=0.7 p1=0.9 α=0.05 β=0.2). Secondary endpoints 
included 36Gy/6f acute toxicity, proportion of Adapted 
fraction, late toxicity (toxicity after 3 months), local 
control and overall survival. Adverse events (AEs) are any 
treatment emergent event and assessed by (CTCAE v4) 
weekly on RT, 4 weeks & 3m post RT. Adverse reactions 
were defined as adverse events related to RT by blinded 
independent review. 
Results  
Between Apr 2014 & Aug 2016 65 pts were randomised 
(SP (n=32) AP (n=33)) from 12 UK sites. Median age was 
85yrs; 68% male; 92% transitional cell MIBC; 31% stage 3-
4, 66% had incomplete resection.   
58/65 (89%) received planned dose with 4/32 SP and 2/33 
AP stopping for toxicity.   
28/33 AP pts had at least one small or large plan 
selected; of all 193 AP treatments 46 (24%) were small 
plan, 117 (60%) medium plan and 30 (16%) large plan. 84% 
of treatments given with plan smaller than SP  
≥G3 acute non-GU emergent treatment related adverse 
reactions (AR) were reported in 2/33 (6%; 90% CI: 1-18%) 
AP and 4/32 (13%; 5-28) SP pts. 5 patients died within 3 
months of randomisation of co-morbidity. 21/65 (32%; 
90% CI: 23%-43%) patients who had more than one 
fraction of radiotherapy experienced ≥G3 acute AEs (of 
any cause). GU Gd 3-4 adverse events were seen in 6 SP 
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and 3 AP patients and Non GU Gd 3-4 in 10 SP and 4 AP 
patients. RTOG Gd 3-4 late toxicity was reported in 1 SP 
patient.  
Local control at 3m was achieved in 38/47 assessed 
patients (81%; 90% CI: 69%-90%). Median survival was 18m 
(95%CI 10-26) and 2 yr survival was 37% (95%CI 23%- 51%). 
 
 
 
Conclusion  
Adaptive Planning in the context of 36Gy in 6f and is 
feasible and met predefined toxicity criteria (<30% ≥G3 
acute non-GU). 85% of AP patients utilised adaption, with 
a trend to less toxicity compared to SP. Hypofractionated 
RT (36Gy/6f) achieves initial local control in >80% of 
patients and acceptable levels of acute and late toxicity. 
Comparative randomised studies are needed to quantify 
benefits of AP over SP. Very elderly patients are willing 
to be randomised to appropriate clinical trials. 
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Purpose or Objective  
Hypofractionated radiotherapy (HFRT) for localised 
prostate cancer (PC) is safe and effective. In times of 
proven effectiveness of different HFRT schedules, it is 
the occurrence of side effects that will determine the 
decision-making which hypofractionation schedule to 
apply. Therefore, we initiated a non-inferiority 
randomized phase 3 study at Ghent University Hospital 
(GUH) with acute toxicity as primary endpoint comparing:  
- 56 Gy delivered in 4 weeks (16 fractions of 3.5 Gy, 4 
days/week, rest on Wednesday, Arm A).  
- 67 Gy delivered in 5 weeks (25 fractions of 2.68 Gy, 5 
days/week, Arm B). 
Material and Methods  
Within this single centre phase 3, non-inferiority trial, PC 
patients were randomly assigned (1:1) to 56 Gray (Gy) 
(Arm A) or 67 Gy (Arm B). Randomization was by 
computer-generated permuted blocks, stratified on prior 
transurethral resection of the prostate and presence of a 
dominant intraprostatic lesion. Treatment allocation was 
not masked. Clinicians were not blinded. The primary 
endpoint is acute toxicity, assessed by CTC version 4.0 
and RTOG. The H0-hypothesis is equivalence of both 
schemes regarding acute grade ≥2 GI toxicity, defined as 
a difference in acute grade ≥2 GI toxicity of ≤ 10%. An 
interim safety analysis was planned after inclusion of the 
first 160 patients to decide whether the study could be 
continued. If >22/72 patients have grade ≥2 GI toxicity, 
the study arm is to be rejected. The study is registered 
on Clinicaltrials.gov (NCT01921803). 
Results  
Between 6/2013 and 7/2016, 160 men were randomly 
assigned (79 to arm A and 81 to arm B).  
Gastro-intestinal (GI) toxicity 
In Arm A, 20 (26%) and 1 (1%) patients developed acute 
grade 2 and grade 3 GI toxicity. In Arm B, 16 (20%) 
reported acute grade 2 GI toxicity.  
In both arms GI toxicity was highest during and at the end 
of HFRT and was significantly increased when compared 
to the status pre-HFRT (Arm A: p<0.0001; Arm B: 
p<0.0001). However, recovery to the status pre-HFRT was 
observed for most patients with time. 
Urinary toxicity 
In Arm A, 42 (55%) and 5 (6%) patients developed acute 
grade 2 and grade 3 urinary toxicity. In Arm B, 40 (49%) 
and 7 (9%) reported acute grade 2 and grade 3 urinary 
toxicity.  
Similar to GI toxicity, urinary toxicity is highest during 
and at the end of EBRT. A clear statistical difference was 
observed for both arms when comparing the situation 
pre-EBRT and during or at the end of EBRT (Arm A: 
p<0.0001; Arm B: p<0.0001). 
Conclusion  
This interim safety analysis of stage 1 of a 2-stage study 
reporting on 2 HFRT schedules confirms that with acute 
grade ≥2 GI toxicity reported in 21/77 patients in arm A 
and 16/82 patients in arm B, the predefined threshold of 
22/72 patients is not exceeded. The study can therefore 
be continued. 
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Purpose or Objective  
In the Dutch phase III HYPRO trial (39x 2 Gy vs. 19x 3.4 
Gy), similar 5-year relapse-free survival rates were 
observed and therefore the hypothesized superiority of 
the hypofractionation (HF) arm was not confirmed. The 
hypothesized non-inferiority with respect to RTOG-EORTC 
grade ≥2 urinary and bowel toxicity was not 
demonstrated, neither were there statistically significant 
differences present between both arms. However, a 
significant increase in grade ≥3 urinary toxicity was 
observed after hypofractionation. In the current analysis 
we evaluated health-related quality of life (QoL), which 
might provide additional insights in the toxicity profiles 
of HF vs conventional fractionation (CF). 
Material and Methods  
In the HYPRO trial, patients with intermediate to high-
risk T1b-T4 localized prostate cancer were recruited 
between 2007-2010 (n=820), and randomized to CF (39x 
2Gy, 5fr/week) or HF (19x 3.4 Gy, 3fr/week). As part of 
the protocol (secondary objective), patients filled out the 
validated prostate cancer specific EORTC Quality of Life 
questionnaire (EORTC-QLQ-PR25). The subscales (score 
range 0-100) on urinary symptoms, bowel symptoms, 
androgen deprivation therapy (ADT)-related symptoms, 
sexual function, and sexual activity were analyzed in a 
linear mixed model with treatment and time as fixed 
effects, and patient as random effect. Changes from 
baseline were assessed and considered small (5-10 
points), moderate (10-20) or large (>20). Significance 
level was set at 0.01 to adjust for multiple testing. 
